1. Home
  2. LLY vs GILD Comparison

LLY vs GILD Comparison

Compare LLY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eli Lilly and Company

LLY

Eli Lilly and Company

N/A

Current Price

$1,004.95

Market Cap

950.7B

Sector

Health Care

ML Signal

N/A

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

N/A

Current Price

$145.95

Market Cap

187.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LLY
GILD
Founded
1876
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
950.7B
187.5B
IPO Year
2007
2000

Fundamental Metrics

Financial Performance
Metric
LLY
GILD
Price
$1,004.95
$145.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
18
Target Price
$1,174.53
$143.50
AVG Volume (30 Days)
2.6M
6.3M
Earning Date
05-04-2026
05-13-2026
Dividend Yield
0.70%
2.28%
EPS Growth
95.99
1684.21
EPS
22.95
6.78
Revenue
$65,179,000,000.00
$24,689,000,000.00
Revenue This Year
$27.04
$4.68
Revenue Next Year
$16.26
$6.10
P/E Ratio
$42.97
$21.23
Revenue Growth
44.70
9.98
52 Week Low
$623.78
$95.30
52 Week High
$1,133.95
$157.29

Technical Indicators

Market Signals
Indicator
LLY
GILD
Relative Strength Index (RSI) 45.69 50.89
Support Level $994.42 $143.09
Resistance Level $1,102.49 $157.29
Average True Range (ATR) 26.48 3.27
MACD -3.52 -1.43
Stochastic Oscillator 39.81 24.02

Price Performance

Historical Comparison
LLY
GILD

About LLY Eli Lilly and Company

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: